Rigel Pharmaceuticals, Inc.
NASDAQ:RIGL
16.44 (USD) • At close December 24, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Rigel Pharmaceuticals, Inc. |
Symbool | RIGL |
Munteenheid | USD |
Prijs | 16.44 |
Beurswaarde | 289,590,600 |
Dividendpercentage | 0% |
52-weken bereik | 7.48 - 29.82 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Raul R. Rodriguez |
Website | https://www.rigel.com |
An error occurred while fetching data.
Over Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)